About: Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients
Creator	Wang, Chen Zhu, Jin Chen, Jiao Chen, Hao Hu, Fen »more»
source	MedRxiv
abstract	Chansu and its major active constituent of bufalin have been reported to have broad-spectrum antiviral effects. This study aims to assess the efficacy of Chansu injection in treating patients with severe COVID-19. The patients diagnosed as severe or critical COVID-19 in The First People's Hospital of Jiangxia District, Wuhan, China from February 5 to March 5, 2020 were randomly allocated in a 1:1 ratio to receive general treatment plus Chansu injection or only general treatment as the control group. The treatment course was 7 days. The changes of PaO2/FiO2 and ROX index indicating respiratory function, the white blood cell (WBC) count, peripheral blood mononuclear lymphocyte (PBML) count, respiratory support step-down time (RSST), and safety indicators for the 7th day were retrospectively analyzed. After 7 days treatment, the oxygenation index was improved in 20 of 21 patients (95.2%) in the treatment group, as compared with 13 of 19 patients (68.4%) in the control group. The PaO2/FiO2 and ROX indices in the treatment group (mean, 226.27 and 14.01 respectively) were significantly higher than the control group (mean, 143.23 and 9.64 respectively). The RSST was 1 day shorter in the treatment group than the control group. Multivariate regression analysis suggested that Chansu injection contributed the most to the outcome of PaO2/FiO2. No obvious adverse effects were observed. Preliminary data showed that Chansu injection had apparent efficacy in treating patients with severe COVID-19.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.20.20107607
has license	medrxiv
sha1sum (hex)	6d84f3d2948f9450da4d42ebc266b6ec89e924e7
schema:url	https://doi.org/10.1101/2020.05.20.20107607
resource representing a document's title	Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients
resource representing a document's body	covid:6d84f3d2948f9450da4d42ebc266b6ec89e924e7#body_text
is schema:about of	named entity 'oxygenation' named entity 'China' named entity 'severe' named entity 'Wuhan' named entity 'compared' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software